Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 6:11:1463305.
doi: 10.3389/fcvm.2024.1463305. eCollection 2024.

Editorial: Therapeutics in pulmonary arterial hypertension

Rui Adão  1   2   3   4 , Francisco Perez-Vizcaino  2   3   4 , Bassam Redwan  5   6 , Carmen Brás-Silva  1   7
Affiliations
Editorial

Editorial: Therapeutics in pulmonary arterial hypertension

Rui Adão et al. Front Cardiovasc Med. .
No abstract available

Keywords: endothelial dysfunction; pulmonary hypertension; pulmonary vascular remodeling; right heart failure; right ventricle; therapy; vascular diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Therapeutics in pulmonary arterial hypertension

References

    1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 Esc/Ers guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. (2023) 61(1):2200879. 10.1183/13993003.00879-2022 - DOI - PubMed
    1. Santos-Ribeiro D, Mendes-Ferreira P, Maia-Rocha C, Adao R, Leite-Moreira AF, Bras-Silva C. Pulmonary arterial hypertension: basic knowledge for clinicians. Arch Cardiovasc Dis. (2016) 109(10):550–61. 10.1016/j.acvd.2016.03.004 - DOI - PubMed
    1. Mulvaney EP, Reid HM, Bialesova L, Mendes-Ferreira P, Adao R, Bras-Silva C, et al. Efficacy of the thromboxane receptor antagonist Ntp42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension. Eur J Pharmacol. (2020) 889:173658. 10.1016/j.ejphar.2020.173658 - DOI - PubMed
    1. Reid HM, Maginn M, Perkins CM, Mulvaney EP, Boyce M, Yamamoto T, et al. Evaluation of Ntp42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial. Front Pharmacol. (2023) 14:1296188. 10.3389/fphar.2023.1296188 - DOI - PMC - PubMed
    1. Balsa A, Adao R, Bras-Silva C. Therapeutic approaches in pulmonary arterial hypertension with beneficial effects on right ventricular function-preclinical studies. Int J Mol Sci. (2023) 24(21):15539. 10.3390/ijms242115539 - DOI - PMC - PubMed

Publication types

LinkOut - more resources